Cargando…

Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK

INTRODUCTION: The results of recently completed cardiovascular outcomes trials in patients with type 2 diabetes mellitus (T2DM) suggest that sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide (GLP) 1 receptor agonists have enhanced cardioprotective properties in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lautsch, Dominik, Wang, Tongtong, Yang, Lingfeng, Rajpathak, Swapnil N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848348/
https://www.ncbi.nlm.nih.gov/pubmed/31583647
http://dx.doi.org/10.1007/s13300-019-00698-9
_version_ 1783469065345433600
author Lautsch, Dominik
Wang, Tongtong
Yang, Lingfeng
Rajpathak, Swapnil N.
author_facet Lautsch, Dominik
Wang, Tongtong
Yang, Lingfeng
Rajpathak, Swapnil N.
author_sort Lautsch, Dominik
collection PubMed
description INTRODUCTION: The results of recently completed cardiovascular outcomes trials in patients with type 2 diabetes mellitus (T2DM) suggest that sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide (GLP) 1 receptor agonists have enhanced cardioprotective properties in patients with established cardiovascular disease (eCVD), but to a lesser degree in those without eCVD. SGLT2 inhibitors appear to be particularly beneficial in patients with heart failure. As recent data for the UK are lacking, we undertook to identify the percentage of T2DM patients with eCVD and heart failure in the UK. METHODS: This was a retrospective cohort study that utilized the Clinical Practice Research Datalink (CPRD) database in the UK. We included de-identified adult patients with T2DM with at least one encounter in the CPRD database between 1 January 2018 and 31 December 2018 in the analysis and extracted the full health records of these patients. eCVD was defined as myocardial infarction, stroke, unstable angina pectoris, coronary artery disease and peripheral artery disease. We further assessed the number of patients with heart failure. RESULTS: From the total of 148,803 patients with T2DM analyzed (53% were male; mean age was 65 years), 52,601 (35.4%) suffered from eCVD and 8650 (5.8%) suffered from heart failure (73.7% of patients with heart failure overlap with those with atherothrombotic eCVD). Glycated hemoglobin levels of < 7% were attained by 49.5% of patients (with eCVD, 49.7%; without eCVD, 49.3%) (p < 0.001). CONCLUSION: Approximately one-third of patients with T2DM in the UK have concomitant CVD. FUNDING: Merck Sharp & Dohme Corp., a subsidiary Merck & Co., Inc., Kenilworth, NJ, USA.
format Online
Article
Text
id pubmed-6848348
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-68483482019-11-22 Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK Lautsch, Dominik Wang, Tongtong Yang, Lingfeng Rajpathak, Swapnil N. Diabetes Ther Original Research INTRODUCTION: The results of recently completed cardiovascular outcomes trials in patients with type 2 diabetes mellitus (T2DM) suggest that sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide (GLP) 1 receptor agonists have enhanced cardioprotective properties in patients with established cardiovascular disease (eCVD), but to a lesser degree in those without eCVD. SGLT2 inhibitors appear to be particularly beneficial in patients with heart failure. As recent data for the UK are lacking, we undertook to identify the percentage of T2DM patients with eCVD and heart failure in the UK. METHODS: This was a retrospective cohort study that utilized the Clinical Practice Research Datalink (CPRD) database in the UK. We included de-identified adult patients with T2DM with at least one encounter in the CPRD database between 1 January 2018 and 31 December 2018 in the analysis and extracted the full health records of these patients. eCVD was defined as myocardial infarction, stroke, unstable angina pectoris, coronary artery disease and peripheral artery disease. We further assessed the number of patients with heart failure. RESULTS: From the total of 148,803 patients with T2DM analyzed (53% were male; mean age was 65 years), 52,601 (35.4%) suffered from eCVD and 8650 (5.8%) suffered from heart failure (73.7% of patients with heart failure overlap with those with atherothrombotic eCVD). Glycated hemoglobin levels of < 7% were attained by 49.5% of patients (with eCVD, 49.7%; without eCVD, 49.3%) (p < 0.001). CONCLUSION: Approximately one-third of patients with T2DM in the UK have concomitant CVD. FUNDING: Merck Sharp & Dohme Corp., a subsidiary Merck & Co., Inc., Kenilworth, NJ, USA. Springer Healthcare 2019-10-04 2019-12 /pmc/articles/PMC6848348/ /pubmed/31583647 http://dx.doi.org/10.1007/s13300-019-00698-9 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Lautsch, Dominik
Wang, Tongtong
Yang, Lingfeng
Rajpathak, Swapnil N.
Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
title Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
title_full Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
title_fullStr Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
title_full_unstemmed Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
title_short Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
title_sort prevalence of established cardiovascular disease in patients with type 2 diabetes mellitus in the uk
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848348/
https://www.ncbi.nlm.nih.gov/pubmed/31583647
http://dx.doi.org/10.1007/s13300-019-00698-9
work_keys_str_mv AT lautschdominik prevalenceofestablishedcardiovasculardiseaseinpatientswithtype2diabetesmellitusintheuk
AT wangtongtong prevalenceofestablishedcardiovasculardiseaseinpatientswithtype2diabetesmellitusintheuk
AT yanglingfeng prevalenceofestablishedcardiovasculardiseaseinpatientswithtype2diabetesmellitusintheuk
AT rajpathakswapniln prevalenceofestablishedcardiovasculardiseaseinpatientswithtype2diabetesmellitusintheuk